about
Current perspectives between metabolic syndrome and cancerCross-Talk between Adiponectin and IGF-IR in Breast CancerCrosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast CancerThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialThe Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated ProteinsTargeting Insulin Receptor with a Novel Internalizing AptamerPhase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.Inhibition of insulin-like growth factor II (IGF-II)-dependent cell growth by multidentate pentamannosyl 6-phosphate-based ligands targeting the mannose 6-phosphate/IGF-II receptor.Obesity, Diabetes and Cancer: A Mechanistic PerspectiveInsulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks TumorigenesisHyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal CancerXIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosisRole of Insulin-like Growth Factor, Insulin-like Growth Factor Receptors, and Insulin-like Growth Factor-binding Proteins in Ovarian Cancer.Regulation of insulin-like growth factor receptors by Ubiquilin1.Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.
P2860
Q26749299-DA2A68F1-1F45-47E9-9A6E-63BB91C0EAA9Q26799865-E915523A-FCF0-4039-AD82-655BEE651832Q26860821-4B2DBE08-1AD2-4D74-9B38-00490F35AA2EQ28075927-7FA444A3-5A61-4080-A53B-A1772BC25F21Q28088661-061AFDFC-A339-4F6E-88CA-C035BD1FF797Q28822291-9907353E-8CFB-4554-976D-6BABD0469D88Q33275887-C800175C-5380-48D1-B130-504105E9BCCAQ36980480-55656ECC-A1C5-4E2D-B5DD-324569FE8090Q37327707-0329DCB3-468E-4B63-9E55-634504444BA5Q37641786-D163CE6B-E846-4D2B-AFEB-9399D1FBA2CDQ37730336-A69F069B-7C73-40C7-86C7-0561BA426900Q38682244-B7A7BBE5-12A8-480E-91FB-15D86C9ACF8EQ38726530-16966D4C-8457-4703-BE56-64B7B8F5E23EQ38912656-8834665C-A33F-4BCF-9227-08CEBEEB2D64Q39519100-B13666D3-EA42-4641-9FBA-8CCAA14BFD11Q41279921-261B99AB-06A5-42F0-A96B-7F71507ACF0CQ41601838-737139DE-E881-4C18-B465-A0069391ADCFQ47621695-699B89BF-CBDB-4E8B-B6BC-E6EE1F7847BFQ47994454-F61CA7CF-A296-4DBB-8A26-2C054CB7EC3AQ52659536-99124D22-1272-4361-8F23-28792175F957
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
IGF-IR Targeted Therapy: Past, Present and Future
@ast
IGF-IR Targeted Therapy: Past, Present and Future
@en
IGF-IR Targeted Therapy: Past, Present and Future
@nl
type
label
IGF-IR Targeted Therapy: Past, Present and Future
@ast
IGF-IR Targeted Therapy: Past, Present and Future
@en
IGF-IR Targeted Therapy: Past, Present and Future
@nl
prefLabel
IGF-IR Targeted Therapy: Past, Present and Future
@ast
IGF-IR Targeted Therapy: Past, Present and Future
@en
IGF-IR Targeted Therapy: Past, Present and Future
@nl
P2860
P3181
P356
P1476
IGF-IR Targeted Therapy: Past, Present and Future
@en
P2093
Aimee J Varewijck
P2860
P3181
P356
10.3389/FENDO.2014.00224
P407
P577
2014-12-23T00:00:00Z